VBL Therapeutics (NASDAQ:VBLT) enrolled the first two patients in its Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer. VB-111 is an adenovirus that...
Tag - VBLT
Copyright © 2024 BioTuesday Publishing Corporation - Privacy Policy